CN110038119A - A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect - Google Patents
A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect Download PDFInfo
- Publication number
- CN110038119A CN110038119A CN201910350090.XA CN201910350090A CN110038119A CN 110038119 A CN110038119 A CN 110038119A CN 201910350090 A CN201910350090 A CN 201910350090A CN 110038119 A CN110038119 A CN 110038119A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- pharmaceutical composition
- synanthrin
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 47
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 14
- 230000000694 effects Effects 0.000 title claims abstract description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 84
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 57
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 57
- 241000251468 Actinopterygii Species 0.000 claims abstract description 45
- 239000001508 potassium citrate Substances 0.000 claims abstract description 33
- 229960002635 potassium citrate Drugs 0.000 claims abstract description 33
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims abstract description 33
- 235000011082 potassium citrates Nutrition 0.000 claims abstract description 33
- 239000001509 sodium citrate Substances 0.000 claims abstract description 31
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 31
- 239000002994 raw material Substances 0.000 claims abstract description 30
- 201000005569 Gout Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 13
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 11
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 47
- 102000008186 Collagen Human genes 0.000 description 18
- 108010035532 Collagen Proteins 0.000 description 18
- 229920001436 collagen Polymers 0.000 description 18
- 235000016709 nutrition Nutrition 0.000 description 14
- 230000035764 nutrition Effects 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 10
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 239000004376 Sucralose Substances 0.000 description 7
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 7
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 7
- 235000019408 sucralose Nutrition 0.000 description 7
- 229940116269 uric acid Drugs 0.000 description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 6
- 240000008892 Helianthus tuberosus Species 0.000 description 6
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 4
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- -1 ion exchange Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 3
- 244000298479 Cichorium intybus Species 0.000 description 3
- 235000007542 Cichorium intybus Nutrition 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 229940118199 levulan Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 229940055726 pantothenic acid Drugs 0.000 description 3
- 235000019161 pantothenic acid Nutrition 0.000 description 3
- 239000011713 pantothenic acid Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000009661 fatigue test Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000001255 hallux Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001906 first metatarsal bone Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Inorganic materials [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention belongs to biomedicine fields, and in particular to a kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect;The pharmaceutical composition is prepared by following raw materials: ocean fish oligopeptide, synanthrin, sodium citrate, potassium citrate and citric acid.Studies have shown that composition of the present invention has antifatigue, anti-trioxypurine pharmacological action, further illustrate, the present composition can be used for patient with gout caused by fatigue.
Description
Technical field
The invention belongs to biomedicine technical fields, specifically contain a kind of medicine group with anti-trioxypurine and antifatigue effect
Close object.
Background technique
Gout is a kind of common and complicated arthritis type, and all age group may suffer from this disease, male's disease incidence
Higher than women.Often there is sudden arthritis at night in patient with gout, and morbidity is anxious, and serious pain occurs in joint part
Bitterly, oedema, redness and inflammation, feeling of pain slowly mitigates until disappearance, takes several days or a few weeks are differed.When panic attacks, suffer from
Person can ache in midnight sleep soundly to wake up, and has patient to describe feeling of pain and is burnt equally similar to big toe.The joint of most commonly-occurring disease is
Big toe (medical terminology: first metatarsal bone), but the joint fallen ill is without being limited thereto, is also common in joint, the knee, ancon of hand
Deng.The eventually red and swollen, inflammation of the joint of morbidity is organized to soften after oedema, and limitation of activity finally influences daily life.
Cause gout essential reason be internal uric acid level raising, cause lithate in joint and renal tract
Deposition.Usually, the main reason for causing gout includes but is not limited to: (1) dietary reasons.Too many meat and sea are eaten
Fresh, after having drunk happily excessive beer, the uric acid level of human body is increased, it is possible to cause uric acid mineralization;(2) fat.It is fat
Caused consequence is the increase of internal uric acid, and kidney can not thoroughly remove extra uric acid;(3) some drugs have been taken.These
Drug will lead to internal uric acid level and increase;(4) family history.If household suffers from gout, the probability of your illness also can be big
It is big to increase.
By the acute arthritis breaking-out condition survey to a large amount of patient with gout, discovery fatigue and high purine diet are the most
Common inducement.Have plenty of continuously work extra shifts or extra hours work, often travel on business trips or move the new home when because excessive fatigue morbidity,
Some is fallen ill after being satiated with food a large amount of fishes, meat product.
Therefore, researching and developing one kind not only has anti-trioxypurine but also has antifatigue product, has important clinical significance.
Summary of the invention
For these reasons, applicant passes through multiple creative research, obtains a kind of new pharmaceutical composition, the composition
It is to be prepared by ocean fish oligopeptide, synanthrin, sodium citrate, potassium citrate and citric acid, studies have shown that of the present invention
Composition have antifatigue, anti-trioxypurine pharmacological action, further illustrate, caused by the present composition can be used for fatigue
Patient with gout.
Special doctor's food of the present invention, refer to must under doctor or clinical nutrition's teacher guidance, it is individually edible or and its
His food is matched.Refer to meet limited feed, Disorder of Digestion and A orption, metabolic disorder or particular disease states crowd couple
The formula food being formulated specially is processed in the special requirement of nutrient or diet.Spy doctor's food is not drug, but is not normal
The ordinary food that people eats, but pass through clinician and a large amount of medical research of nutritionists, the objective fact with science is
According to the special formula food developed, produced.When target group can not feed full diet or can not meet it with ordinary meal
When nutritional need, special medicine purposes formula food can be used as a kind of nutritional supplementation approach, play the role of nutritional support.The food
Product are unable to the therapeutic effect of alternative medicine, and product must not also claim prevention of disease and treatment function.
Ocean fish oligopeptide of the present invention meets " ocean fish oligopeptide powder (GB/T 22729-2008) ", marine fish
Collagen oligopeptide is using pollution-free or the relatively small deep-sea fish of pollution skin, bone as raw material, and purification is process.
Synanthrin of the present invention refers to inulin or natural levulan, and to be with jerusalem artichoke (Jerusalem artichoke) rhizomes be or witloof is former
Material, removes removing protein, colloid, crude fibre and minerals, extracts through water, ion exchange, and film filtering, the production technologies such as spray drying obtain
To synanthrin.
The present invention is achieved through the following technical solutions.
A kind of pharmaceutical composition, the pharmaceutical composition are prepared by following raw materials: ocean fish oligopeptide, synanthrin, lemon
Sour sodium, potassium citrate and citric acid.
Preferred pharmaceutical composition, wherein ocean fish oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate
10-15 parts by weight, potassium citrate 10-15 parts by weight and citric acid 1-5 parts by weight.
Further preferred pharmaceutical composition, wherein 3 parts by weight of ocean fish oligopeptide, 15 parts by weight of synanthrin, potassium citrate
4 parts by weight of 14 parts by weight, 12 parts by weight of sodium citrate and citric acid.
The application of pharmaceutical composition described above in preparation treatment gout drug.
Pharmaceutical composition described above is preparing the application in anti-trioxypurine drug.
Pharmaceutical composition described above is preparing the application in antifatigue drug.
Pharmaceutical composition described above is applied in preparing anti-trioxypurine spy doctor's food.
A kind of pharmaceutical composition for treating gout effect, the pharmaceutical composition are prepared by following raw materials: marine fish is low
Poly- peptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight and citric acid
1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide, 15 weight of synanthrin
Part, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
A kind of pharmaceutical composition with anti-trioxypurine effect, is prepared in the pharmaceutical composition by following raw materials: ocean
Fish oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight and lemon
Lemon acid 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide, 15 weight of synanthrin
Measure part, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
A kind of pharmaceutical composition with antifatigue effect, the pharmaceutical composition are prepared by following raw materials: marine fish
Oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight and lemon
Sour 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide, 15 weight of synanthrin
Part, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
Ocean fish oligopeptide of the present invention meets " ocean fish oligopeptide powder (GB/T 22729-2008) ", marine fish
Collagen oligopeptide is using pollution-free or the relatively small deep-sea fish of pollution skin, bone, meat as raw material, and purification is process.This hair
The bright ocean fish oligopeptide are as follows: marine fish skin collagen oligopeptide, Marine fishbone collagen oligopeptide, ocean fish oligopeptide.
Synanthrin of the present invention refers to inulin or natural levulan, be using jerusalem artichoke (Jerusalem artichoke) rhizomes or witloof as raw material,
Removing protein, colloid, crude fibre and minerals are removed, are extracted through water, ion exchange, film filters, and the production technologies such as spray drying obtain
Synanthrin.
Pharmaceutical composition of the present invention can be prepared into oral solid formulation, and other supplementary material systems can also be added
For at granule.
D-sorbite, isomaltoketose (palatinose, isomery sugarcane can also be added in pharmaceutical composition of the present invention
Sugar), nutrition enhancer premix, one or more of Sucralose, be prepared into composite powder.
The nutrition enhancer premix includes the component of following parts by weight: 130-140 parts of taurine, Catergen 20-
230 parts, 0-20 parts of vitamin e1,0.5-1 parts of beta carotene, vitamin B22-3 parts, vitamin B61-2 parts, pantothenic acid 5-10
Part, 0.05-2 parts of folic acid.
Preferred nutrition enhancer premix includes the component of following parts by weight: 140 parts of taurine, 225 parts of vitamin C,
18 parts of vitamin E, 0.6 part of beta carotene, vitamin B22.2 parts, vitamin B61.81 parts, 8 parts of pantothenic acid, folic acid 0.06
Part.
Supplementary material source of the present invention is shown in Table 1.
The supplementary material source of the present invention of table 1
The present invention is to be aided with sodium citrate, potassium citrate and citric acid based on ocean fish oligopeptide and synanthrin, for easy
It is taken in the patient with gout of fatigue, is to carry out using rather than ordinary food under the guidance of clinician or nutritionist;In sea
On the basis of foreign fish oligopeptide, synanthrin, sodium citrate, potassium citrate and citric acid, D-sorbite, different malt ketone can also be added
One or more of sugared (palatinose, isomery sucrose), nutrition enhancer premix, Sucralose.
Specific embodiment
Below the technical scheme of the invention is illustrated by a specific example, but the scope of the present invention is not limited thereto.
Content described in this specification embodiment is only enumerating to the way of realization of inventive concept, protection of the invention
Range should not be construed as being limited to the specific forms stated in the embodiments, and protection scope of the present invention is also and in art technology
Personnel conceive according to the present invention it is conceivable that equivalent technologies mean.Although embodiment of the invention below is retouched
It states, but the invention is not limited to above-mentioned specific embodiments and applications field, following specific embodiments is only to show
It is meaning property, guiding, rather than it is restrictive.Those skilled in the art under the enlightenment of this specification and are not taking off
In the case where the range protected from the claims in the present invention, a variety of forms can also be made, these belong to the present invention
The column of protection.
The following tests of the present invention are on the basis of multiple creative test, with the claimed technical solution of the present invention
Based on, the conclusive test of the research staff of summary.Quantitative test in following embodiment, is respectively provided with three repeated experiments,
Data are the average value or mean+SD of three repeated experiments.
Following tests entrust grand reputation wing Yao (Beijing) Science and Technology Ltd. to complete by applicant.
Test the influence of 1 pair of mouse hyperuricemia
Test group:
Test 1 group: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g;
Test 2 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, sodium citrate 2.6g;
Test 3 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, potassium citrate 2.6g;
Test 4 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, natrium malicum 1.73g;
Test 5 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, sodium bicarbonate 0.74g;
Test 6 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, potassium citrate 1.4g, sodium citrate 1.2g.
Test 7 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, potassium citrate 2.6g, citric acid 0.4g.
Test 8 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, potassium citrate 1.4g, sodium citrate 1.2g and lemon
Lemon acid 0.4g.
Test method: kunming mice, male, 18~22g of weight is random to be grouped, blank control group, model group, test group,
Every group 10, in addition to naive mice, equal stomach-filling Oteracil Potassium (100mg/kg) modeling of other group of every morning, of the present invention group every
Give raw material 3.5g/kg its afternoon, the distilled water of same volume is given in model group stomach-filling in afternoon.Each group is administered once daily, and is given altogether
Medicine 30d, the 30d during administration carry out index of correlation detection.Indexs measure: fasting 12h (can't help before formal experiment starts
Water), and blood 1mL first is taken from eye socket before administration, after being placed at room temperature for 2h, centrifugation (4000r/min, 15min) separates serum, put-
20 DEG C spare, horizontal for the serum UA before test experience.Take blood examination to survey with same method within the 30d days in administration, after 30d in addition to
It is horizontal to detect UA.
Test result is shown in Table 1:
Influence of the table 1 to hyperuricemia mouse uric acid
Note: P < 0.05 * * P < 0.01, * compared with model group;##P < 0.01 compared with 0d, #P < 0.05.
Conclusion (of pressure testing): after raising 30d, compared with blank group, model group UA horizontal significantly raised (p < 0.01), explanation is made
Mould success;Compared with model group, the UA that 8 groups of 2 groups-test of test can reduce hyperuricemia mouse is horizontal, has significant
Sex differernce (P < 0.05), although and testing 1 group and analyzing the UA level for having reduction hyperuricemia mouse, and model from data
Group is relatively without statistical difference;It absolutely proves, 8 groups of 2 groups-test of test has certain anti-trioxypurine effect.
Test 2 anti-fatigue tests
Test method: Kunming mouse, weight 18-20g are taken.Random grouping, every group 10, control group gives physiological saline
0.2ml/20g.1 each test group gastric infusion is tested, mouse is quickly put into advance by dosage 3.5g/kg after administration 1 hour
In the swimming pool got ready, record mouse enters pond and starts to the time no longer swum.It the results are shown in Table 2.
Trial drug: see test 1.
2 anti-fatigue test result of table
Note: compared with the control group, P < 0.05 * * P < 0.01, *.
Test result: show 1 group to 7 groups of test of test in terms of antifatigue from above-mentioned test data, have with control group aobvious
It writes sex differernce (P < 0.05);And 8 groups are tested at antifatigue aspect, there is extremely significant difference (P < 0.01) with control group.
Test 3 stability tests
Test method:
(1) exposure experiments to light: test 1- is taken to test 7 raw materials, loose to divide in small culture dish, thickness about 5mm.It places it in
Drug strong illumination chamber is placed 10 days under the conditions of Yu Zhaodu 4500Lx ± 500Lx, in the 5th day and the 10th day sample detection
Relative molecular weight is lower than the content of 1000u oligopeptide (small peptide), as a result compared with 0 month data.
(2) hot test: taking test 1- to test 7 raw materials, be placed in small beaker, sealing film sealing.Place it in electric heating drum
Wind drying box is placed 10 days under the conditions of 60 DEG C ± 1 DEG C, is lower than 1000u in the 5th day and the 10th day sample detection relative molecular weight
The content of oligopeptide (small peptide), as a result compared with 0 month data.
(3) high humidity test: take test 1- test 7 raw materials, be placed in small beaker, be respectively placed in fill NaCl saturated solution and
KNO3The close drying device of saturated solution, damp condition are respectively RH75%.It is respectively placed in electric drying oven with forced convection, 25
It is placed 10 days under the conditions of DEG C ± 1 DEG C, is lower than 1000u oligopeptide (small peptide) in the 5th day and the 10th day sample detection relative molecular weight
Content, as a result compared with 0 month data.
Trial drug: 7 groups of 1 group-test are tested in test 1
Detection method: according to the detection method in GB/T 22729-2008.
Test result is shown in Table 3, table 4, table 5.
3 exposure experiments to light result of table
4 high temperature test result of table
5 high humidity test result of table
Conclusion (of pressure testing): it is above-mentioned experiments have shown that, Marine fishbone collagen oligopeptide and synanthrin composition stability are preferable, and again plus
Enter sodium citrate or potassium citrate or citric acid or natrium malicum or sodium bicarbonate, will lead to Marine fishbone collagen oligopeptide in height
It degrades under wet environment, content is caused not meet quality criteria requirements (standard are as follows: be more than or equal to 85%);And be added sodium citrate,
The group of potassium citrate and citric acid, Marine fishbone collagen oligopeptide are hardly degraded;Therefore, the comprehensive pharmacology examination of inventor
It tests, 8 groups of retention test are raw material of the present invention.
Prepare embodiment
Embodiment 1
D-sorbite 3000g, synanthrin 1500g, isomaltoketose 1000g, potassium citrate 1000g, sodium citrate 1000g,
Citric acid 100g, ocean fish oligopeptide 200g, nutrition enhancer premix 50g, Sucralose 10g.Above-mentioned raw materials mixing is complete
To obtain the final product.
Embodiment 2
D-sorbite 4000g, synanthrin 2000g, isomaltoketose 1500g, potassium citrate 1500g, sodium citrate 1500g,
Citric acid 500g, ocean fish oligopeptide 500g, nutrition enhancer premix 300g, Sucralose 50g.Above-mentioned raw materials mixing is complete
To obtain the final product.
Embodiment 3
D-sorbite 3630g, synanthrin 1500g, isomaltoketose 1500g, potassium citrate 1400g, sodium citrate 1200g,
Citric acid 400g, ocean fish oligopeptide 300g, nutrition enhancer premix 50g, Sucralose 20g.Above-mentioned raw materials mix to obtain the final product.
Embodiment 4
D-sorbite 3200g, synanthrin 1650g, isomaltoketose 1200g, potassium citrate 1200g, sodium citrate 1150g,
Citric acid 120g, ocean fish oligopeptide 220g, nutrition enhancer premix 65g, Sucralose 12g.Above-mentioned raw materials mix to obtain the final product
Embodiment 5
D-sorbite 3850g, synanthrin 1850g, isomaltoketose 1400g, potassium citrate 1450g, sodium citrate 1350g,
Citric acid 450g, ocean fish oligopeptide 400g, nutrition enhancer premix 250g, Sucralose 40g.
In above-described embodiment in nutrition enhancer premix raw material proportionate relationship are as follows: 140 parts of taurine, vitamin C
225 parts, 18 parts of vitamin E, 0.6 part of beta carotene, vitamin B22.2 parts, vitamin B61.81 parts, 8 parts of pantothenic acid, folic acid
0.06 part.
Ocean fish oligopeptide of the present invention meets " ocean fish oligopeptide powder (GB/T 22729-2008) ", marine fish
Collagen oligopeptide is using pollution-free or the relatively small deep-sea fish of pollution skin, bone, meat as raw material, and purification is process.This hair
The bright ocean fish oligopeptide are as follows: marine fish skin collagen oligopeptide, Marine fishbone collagen oligopeptide, ocean fish oligopeptide.
Synanthrin of the present invention refers to inulin or synanthrin or natural levulan, is with jerusalem artichoke (Jerusalem artichoke) rhizomes or witloof
For raw material, removing protein, colloid, crude fibre and minerals are removed, are extracted through water, ion exchange, film filtering, the production work such as spray drying
Skill obtains synanthrin.
Pharmaceutical composition of the present invention can be prepared into oral solid formulation, and other supplementary material systems can also be added
For at granule.
Pharmaceutical composition (composition including embodiment) of the present invention, can be used alone, to treat or in advance
Anti- gout breaking-out, can also be with the drug combination, such as Febustat, colchicin, Allopurinol, Benzbromarone etc. for the treatment of gout
Drug.
Claims (10)
1. a kind of pharmaceutical composition, it is characterised in that the pharmaceutical composition is prepared by following raw materials: ocean fish oligopeptide, chrysanthemum
Sugar, sodium citrate, potassium citrate and citric acid.
2. a kind of pharmaceutical composition according to claim 1, wherein ocean fish oligopeptide 2-5 parts by weight, synanthrin 15-20 are heavy
Measure part, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight and citric acid 1-5 parts by weight.
3. a kind of pharmaceutical composition according to claim 1, wherein 3 parts by weight of ocean fish oligopeptide, 15 parts by weight of synanthrin,
4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
4. a kind of pharmaceutical composition according to claim 1-3, it is characterised in that prepared by the pharmaceutical composition
Treat the application in gout drug.
5. a kind of pharmaceutical composition according to claim 1-3, it is characterised in that prepared by the pharmaceutical composition
Application in anti-trioxypurine drug.
6. a kind of pharmaceutical composition according to claim 1-3, it is characterised in that prepared by the pharmaceutical composition
Anti-trioxypurine spy cures to apply in food.
7. a kind of pharmaceutical composition according to claim 1-3, it is characterised in that prepared by the pharmaceutical composition
Anti-trioxypurine spy cures to apply in food.
8. a kind of pharmaceutical composition for treating gout effect, it is characterised in that the pharmaceutical composition is prepared by following raw materials:
Ocean fish oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight
With citric acid 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide, synanthrin
15 parts by weight, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
9. a kind of pharmaceutical composition with anti-trioxypurine effect, it is characterised in that the pharmaceutical composition prepared by following raw materials and
At: ocean fish oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 weight
Measure part and citric acid 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide,
15 parts by weight of synanthrin, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
10. a kind of pharmaceutical composition with antifatigue effect, it is characterised in that: the pharmaceutical composition prepared by following raw materials and
At: ocean fish oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 weight
Measure part and citric acid 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide,
15 parts by weight of synanthrin, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910350090.XA CN110038119A (en) | 2019-04-28 | 2019-04-28 | A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect |
PCT/CN2020/087150 WO2020221192A1 (en) | 2019-04-28 | 2020-04-27 | Pharmaceutical composition having uric acid-lowering and anti-fatigue effects |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910350090.XA CN110038119A (en) | 2019-04-28 | 2019-04-28 | A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110038119A true CN110038119A (en) | 2019-07-23 |
Family
ID=67280069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910350090.XA Pending CN110038119A (en) | 2019-04-28 | 2019-04-28 | A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110038119A (en) |
WO (1) | WO2020221192A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020221184A1 (en) * | 2019-04-28 | 2020-11-05 | 杭州泽健医药科技有限公司 | Pharmaceutical composition with effect of reducing uric acid |
WO2020221192A1 (en) * | 2019-04-28 | 2020-11-05 | 杭州泽健医药科技有限公司 | Pharmaceutical composition having uric acid-lowering and anti-fatigue effects |
CN112369609A (en) * | 2020-10-30 | 2021-02-19 | 云南奥咖生物技术有限公司 | Functional food capable of reducing uric acid and preparation method thereof |
CN114736946A (en) * | 2022-06-10 | 2022-07-12 | 广东海洋大学 | Preparation method and application of marine fish oligopeptide with functions of resisting fatigue and reducing uric acid |
CN117100836A (en) * | 2023-10-16 | 2023-11-24 | 健码制药(广东)有限公司 | Ganoderma lucidum and fructus alpiniae oxyphyllae marine fish oligopeptide composition and application thereof in preventing or treating hyperuricemia and resisting fatigue |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070099846A1 (en) * | 2003-05-30 | 2007-05-03 | Lytone Enterprise, Inc. | Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide |
JP2009102248A (en) * | 2007-10-22 | 2009-05-14 | Lytone Enterpprise Inc | Pharmaceutical composition for rapidly decreasing uric acid in blood and package, and use of anserine for rapidly decreasing uric acid in blood |
CN105126067A (en) * | 2015-09-30 | 2015-12-09 | 北京知蜂堂蜂产品有限公司 | Composition for reducing uric acid and application thereof |
CN105380962A (en) * | 2015-12-11 | 2016-03-09 | 汤臣倍健股份有限公司 | Uric acid reducing composition and preparation thereof |
CN106135907A (en) * | 2015-04-11 | 2016-11-23 | 青岛贝尔特生物科技有限公司 | A kind of alimentation composition contributing to resisting fatigue |
CN106805234A (en) * | 2016-12-19 | 2017-06-09 | 江苏红瑞制药有限公司 | A kind of anti-trioxypurine food compositions |
CN109122859A (en) * | 2018-11-01 | 2019-01-04 | 威海健康生生物科技有限公司 | Anti-trioxypurine composition and the preparation method and application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1323675C (en) * | 2004-01-19 | 2007-07-04 | 张冰 | Novel usage of chicory aqueous extract |
CN105029447B (en) * | 2015-08-11 | 2019-03-22 | 湖南科尔生物技术有限公司 | A kind of ocean fish oligopeptide powder containing active probiotic |
CN105614860A (en) * | 2016-01-22 | 2016-06-01 | 湖南营养树科技有限公司 | Probiotic compound oligopeptide nutritional supplement capable of lowering uric acid |
CN107594520A (en) * | 2017-09-20 | 2018-01-19 | 湖南慧泽生物医药科技有限公司 | A kind of formula food eaten for patient with gout |
CN108841908A (en) * | 2018-08-03 | 2018-11-20 | 福建中医药大学 | A kind of preparation method with the active marine oligopeptide of anti-trioxypurine |
CN110038119A (en) * | 2019-04-28 | 2019-07-23 | 杭州泽健医药科技有限公司 | A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect |
-
2019
- 2019-04-28 CN CN201910350090.XA patent/CN110038119A/en active Pending
-
2020
- 2020-04-27 WO PCT/CN2020/087150 patent/WO2020221192A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070099846A1 (en) * | 2003-05-30 | 2007-05-03 | Lytone Enterprise, Inc. | Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide |
JP2009102248A (en) * | 2007-10-22 | 2009-05-14 | Lytone Enterpprise Inc | Pharmaceutical composition for rapidly decreasing uric acid in blood and package, and use of anserine for rapidly decreasing uric acid in blood |
CN106135907A (en) * | 2015-04-11 | 2016-11-23 | 青岛贝尔特生物科技有限公司 | A kind of alimentation composition contributing to resisting fatigue |
CN105126067A (en) * | 2015-09-30 | 2015-12-09 | 北京知蜂堂蜂产品有限公司 | Composition for reducing uric acid and application thereof |
CN105380962A (en) * | 2015-12-11 | 2016-03-09 | 汤臣倍健股份有限公司 | Uric acid reducing composition and preparation thereof |
CN106805234A (en) * | 2016-12-19 | 2017-06-09 | 江苏红瑞制药有限公司 | A kind of anti-trioxypurine food compositions |
CN109122859A (en) * | 2018-11-01 | 2019-01-04 | 威海健康生生物科技有限公司 | Anti-trioxypurine composition and the preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
李怡芳等: "营养型鸡精抗疲劳作用的研究现状", 《今日药学》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020221184A1 (en) * | 2019-04-28 | 2020-11-05 | 杭州泽健医药科技有限公司 | Pharmaceutical composition with effect of reducing uric acid |
WO2020221192A1 (en) * | 2019-04-28 | 2020-11-05 | 杭州泽健医药科技有限公司 | Pharmaceutical composition having uric acid-lowering and anti-fatigue effects |
CN112369609A (en) * | 2020-10-30 | 2021-02-19 | 云南奥咖生物技术有限公司 | Functional food capable of reducing uric acid and preparation method thereof |
CN114736946A (en) * | 2022-06-10 | 2022-07-12 | 广东海洋大学 | Preparation method and application of marine fish oligopeptide with functions of resisting fatigue and reducing uric acid |
CN117100836A (en) * | 2023-10-16 | 2023-11-24 | 健码制药(广东)有限公司 | Ganoderma lucidum and fructus alpiniae oxyphyllae marine fish oligopeptide composition and application thereof in preventing or treating hyperuricemia and resisting fatigue |
CN117100836B (en) * | 2023-10-16 | 2024-01-26 | 健码制药(广东)有限公司 | Ganoderma lucidum and fructus alpiniae oxyphyllae marine fish oligopeptide composition and application thereof in preventing or treating hyperuricemia and resisting fatigue |
Also Published As
Publication number | Publication date |
---|---|
WO2020221192A1 (en) | 2020-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110038119A (en) | A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect | |
CN101822383B (en) | Functionality nutritional meal replacing food suitable for tumor patient and preparation method thereof | |
CN102077936B (en) | Special sea dietary food for diabetics | |
CN102077940B (en) | Special dietary marine food for patients with coronary heart disease | |
CN102077934B (en) | Special dietary marine food for patients with high blood pressure | |
CN107183705A (en) | A kind of relax bowel improves the functional food of constipation | |
CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
CN108175089A (en) | A kind of full nutrient formulation liquid suitable for diabetic | |
CN110051002A (en) | A kind of pharmaceutical composition with anti-trioxypurine effect | |
CN102077937A (en) | Special dietary seafood special for young and middle-aged women | |
CN102077944B (en) | Marine special dietary food special for prostate patient | |
CN107397208A (en) | Using fish glue as functional food of principal component and application thereof | |
CN109247585A (en) | A kind of full nutrition special medicine purposes formula food for trauma patient | |
CN107616507A (en) | A kind of ocean polypeptide spy's dietary seafood for chornic arthritis edible for patients | |
CN108782679A (en) | A kind of weight-reducing intervention is dry and preparation method thereof for refreshment | |
CN110354236A (en) | A kind of pharmaceutical composition and preparation method thereof for treating sympotoms caused by cold factors | |
CN102077943B (en) | Seafood for special dietary uses for hypomnesia patients | |
CN102389562A (en) | Traditional Chinese medicine composition for treating indigestion in children | |
CN102335222B (en) | Pharmaceutical composition for adjusting blood fat and preparation process thereof | |
CN108771081A (en) | Haematococcus pluvialis citrus fruit fibres compound solid beverage of weight-reducing and preparation method thereof | |
CN105191859A (en) | Production method of low-cholesterol potassium-rich carotene-rich egg | |
CN108851071A (en) | Sea-buckthorn VP alimentation composition and its preparation method and application | |
Mokolensang et al. | Incorporation of macroalgae to fish feed lowers allergenic properties in fish: An opinion study | |
WO2011142489A1 (en) | Natural food composition for improving constipation, prescribed on the basis of the physical constitution of a patient | |
Gryszkin et al. | Ganotherapy in sports |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190723 |
|
RJ01 | Rejection of invention patent application after publication |